Navigation Links
Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Date:11/24/2009

of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the potential for, and timing of, filing an NDA for Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: additional analyses of data from the Contrave Phase 3 trials and any other clinical trials of Contrave may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted clinical trials; the FDA may not agree with the Company's interpretation of efficacy and safety results; the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDA for Contrave; the third parties on whom Orexigen relies to assist with the development programs for Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry ou
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... WASHINGTON , April 20, 2015  In ... nation,s healthcare markets, the FTC announced that Cardinal ... it illegally monopolized 25 local markets for the ... hospitals and clinics to pay inflated prices for ... to pay $26.8 million of ill-gotten gains and ...
(Date:4/20/2015)... April 20, 2015  Purdue Pharma, a leading ... Butcher has joined the company as Senior ... will have responsibility for all of Purdue,s efforts ... products that would benefit from our patient-focused commercial ... leader," said Purdue President & CEO Mark ...
(Date:4/20/2015)... YORK , April 20, 2015 ... pump market will continue to be robust; the ... incidence of diabetes, expanding global markets, new product ... there are relatively steady market inhibitors, such as ... an increasing competitive environment. The healthcare market research ...
Breaking Medicine Technology:Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 2Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 3Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 4Cardinal Health Agrees to Pay $26.8 Million to Settle Charges It Monopolized 25 Markets for the Sale of Radiopharmaceuticals to Hospitals and Clinics, says FTC 5Purdue Pharma Names J. Alan Butcher Senior Vice President of Licensing & Business Development 2Kalorama: Insulin Pump Market Growing Robustly 2Kalorama: Insulin Pump Market Growing Robustly 3
... TARRYTOWN, N.Y., Oct. 15 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... the 17th Annual NewsMakers in the Biotech Industry Conference ... for 9:00 a.m. Eastern Time.  The session may be ... on the Investor Relations page.  An archived version of ...
... Oct. 15 EntreMed, Inc. (Nasdaq: ... for the treatment of cancer, today announced that ... Stock Market indicating that it has regained compliance ... Listed Securities ("MVLS") requirement for continued listing on ...
Cached Medicine Technology:EntreMed Receives Notice of NASDAQ Compliance 2
(Date:4/20/2015)... 1% for the Planet , one ... that Kate Williams, the network’s Director of Partnerships, will step ... Williams has been part of 1% for the Planet since ... of the Northern Forest Canoe Trail, a 1% for the ... the stewardship of and advocacy for the outdoors, a commitment ...
(Date:4/20/2015)... 20, 2015 Today the members ... Research Fund-Ovarian Cancer National Alliance-National Ovarian Cancer Coalition ... Team will focus on “DNA Repair Therapies for ... identified DNA repair as a common weakness in ... and early detection of ovarian cancer by developing ...
(Date:4/20/2015)... Grateful Dead originally formed in 1965 ... 1995. The group was more than just about rock music. ... space rock, country, and other genres to put together their ... The group was inducted into the Rock and Roll Hall ... than 35 million records worldwide. This year marks the ...
(Date:4/20/2015)... New York (PRWEB) April 20, 2015 ... Centers for Medicare & Medicaid Services introduced their new ... HCAHPS (Hospital Consumer Assessment of Healthcare Providers and Systems) ... survey asks patients about their experiences during a recent ... results from July 1, 2013 through June 30, 2014 ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Insuranceautoquote.info has ... find affordable car insurance quotes online . , ... for the best results. Clients should always compare online ... be done on a single website: . http://insuranceautoquote.info ... The questionnaire can be completed in a few minutes ...
Breaking Medicine News(10 mins):Health News:1% for the Planet Announces New CEO 2Health News:1% for the Planet Announces New CEO 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 2Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 3Health News:New Ovarian Cancer Dream Team to Research DNA Repair Therapies 4Health News:Grateful Dead Tickets at Levi’s Stadium in Santa Clara: Ticket Down Slashes Grateful Dead Tickets in Santa Clara @ Levi’s Stadium for "Fare Thee Well" 50th Anniversary 2Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 2Health News:Northern Westchester Hospital Named a 5-Star Hospital In Medicare's Patient Satisfaction Rating 3Health News:Affordable Auto Insurance Quotes Can Be Found Online, Fast and Easy 2
... BOSTON, Sept. 15 The 13th Annual ... (HFSA) today featured a discussion titled "Cardiovascular Disease in ... Chen, Director, Stress Echocardiography Program and Program for Cardiac ... Dr. Chen,s presentation highlights the increased risk of heart ...
... , , , ... HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ... use of Nexavar((R)) (sorafenib) tablets across tumor types - as ... will be presented at the joint 15th European CanCer Organisation ...
... CRANBURY, N.J., Sept. 15 Palatin Technologies, Inc. ... on clinical trial results with PL-3994, its product for heart ... Meeting of the Heart Failure Society of America in Boston. ... of PL-3994 in controlled hypertensive volunteers who were taking antihypertensive ...
... , , , ... abstract artist Susan Olmetti , one must only step ... step into the company of unconventional characters housed in an outlying charismatic ... mid-1800s and currently inhabited by more than 75 locally owned, independent businesses ...
... ALEXANDRIA, Va., Sept. 15 For overweight men ... cholesterol, high blood pressure, high blood sugar/glucose, poor diet and ... efforts to lose weight, according to Building Healthier America, a ... overweight and obesity in the U.S. , , ...
... , , , CAPE ... experiencing growth across a range of sectors. However, the drive ... medical imaging devices. , , (Logo: ... Frost & Sullivan ( http://www.medicaldevices.frost.com ), Overview ...
Cached Medicine News:Health News:Presentation at Annual Meeting Highlights Increased Risk of Heart Failure in Childhood Cancer Survivors 2Health News:Presentation at Annual Meeting Highlights Increased Risk of Heart Failure in Childhood Cancer Survivors 3Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 2Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 3Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 4Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 5Health News:Bayer and Onyx Announce Nexavar Data Presentations at the Joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress 6Health News:Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting 2Health News:Palatin Technologies, Inc. Announces PL-3994 Poster Presentation at 2009 Heart Failure Society of America Annual Meeting 3Health News:Wine Reception Mixing up one Part Abstract Artist Susan Olmetti, one Part Chicago House Fundraiser, and one Part SIR Spa 2Health News:Building Healthier America Announces the 'High Five' Program Addressing Factors Affecting the Energy Levels of Overweight Men 2Health News:Building Healthier America Announces the 'High Five' Program Addressing Factors Affecting the Energy Levels of Overweight Men 3Health News:Medical Imaging Equipment Finds Significant Uptake in Ghana, Finds Frost & Sullivan 2Health News:Medical Imaging Equipment Finds Significant Uptake in Ghana, Finds Frost & Sullivan 3
Sealing Mat for 96-well, 2.0ml, Deep Well, Square Available Sterile...
96-well Silicone Compression Mat, Bulk...
Silicone Compression Mat, Bulk...
96-well Silicone Expansion Mat, Bulk...
Medicine Products: